<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297308</url>
  </required_header>
  <id_info>
    <org_study_id>TIS2014-001</org_study_id>
    <nct_id>NCT02297308</nct_id>
  </id_info>
  <brief_title>A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications</brief_title>
  <official_title>A Single Center, Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Terumo Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective, single center data collection to assess bleeding and vascular
      complications associated with TAVI when a SoloPath® Balloon Expandable TransFemoral
      Introducer is used for vascular access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to collect data on the rate of vascular complications in subjects
      having transfemoral TAVI when the SoloPath® Balloon Expandable TransFemoral Introducer is
      used as a guide for introduction and delivery of TAVI devices. The use of a small profile
      sheath could possibly reduce the incidence of post procedure vascular complications
      associated with TAVI and further enhance the safety of accessing the femoral delivery route.

      In addition, this study will examine the impact of arterial morphology and other subject risk
      factors as a predictor of clinical outcomes within 30 days following TAVI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Access Site Complications</measure>
    <time_frame>withn 30 days of TAVI procedure</time_frame>
    <description>Rate of VARC-2 defined vascular complications within 30 days of TAVI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Complications at the Access Site</measure>
    <time_frame>within 30 days of TAVI procedure</time_frame>
    <description>VARC-2 defined vascular access site bleeding complications i.e. minor, major or life threatening bleeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Vascular Access Complication</condition>
  <arm_group>
    <arm_group_label>SoloPath Sheath</arm_group_label>
    <description>The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of subjects with severe aortic stenosis who underwent
        TAVI utilizing the SoloPath sheath for vascular access since 2011.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have undergone a TAVI procedure with femoral access achieved with a 19Fr
             (ID) SoloPath (STFI) sheath.

          2. Male or female ≥ 18 years old.

        Exclusion Criteria:

          1. Subjects with Femoral or Iliac vessels less than 6mm on side of TAVI access will be
             excluded.

          2. Subjects treated before January 1, 2011, are excluded from this analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Asagr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <results_first_submitted>November 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2016</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between October 7th, 2014 and February 9th, 2015 at the Montreal Heart Institute.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SoloPath Sheath</title>
          <description>The study focused on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascular access.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SoloPath Sheath</title>
          <description>The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vascular Access Site Complications</title>
        <description>Rate of VARC-2 defined vascular complications within 30 days of TAVI.</description>
        <time_frame>withn 30 days of TAVI procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SoloPath Sheath</title>
            <description>Vascular Complications</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Access Site Complications</title>
          <description>Rate of VARC-2 defined vascular complications within 30 days of TAVI.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Complications at the Access Site</title>
        <description>VARC-2 defined vascular access site bleeding complications i.e. minor, major or life threatening bleeding</description>
        <time_frame>within 30 days of TAVI procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SoloPath Sheath</title>
            <description>Rate of VARC-2 defined access site bleeding complications.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Complications at the Access Site</title>
          <description>VARC-2 defined vascular access site bleeding complications i.e. minor, major or life threatening bleeding</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not assessed as this was a retrospective study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SoloPath Sheath</title>
          <description>The study focused on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascular access.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall be permitted to publish the results of the study in a manner that fairly and accurately sets forth the conclusions reached. The party seeking publication shall submit to the sponsor for review a draft of the proposed publication at least thirty (30) days prior to submission of the draft for publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single center, retrospective data analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Gash, Director of Clinical Affairs</name_or_title>
      <organization>Terumo Medical Corporation</organization>
      <phone>732-302-4931</phone>
      <email>robert.gash@terumomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

